Covalent Group, Inc. Announces $2.9 Million Contract to Conduct Clinical Trials of Bio-Artificial Liver in Patients With Severe Hepatic Disease

Apr 04, 2001, 01:00 ET from Covalent Group, Inc.

    WAYNE, Pa., April 4 /PRNewswire/ -- Covalent Group, Inc. (Nasdaq:   CVGR)
 announced today the signing of a $2.9 million contract with VitaGen, Inc., a
 privately held biotechnology and medical products company located in La Jolla,
 CA.  Covalent will provide advanced consultative and clinical development
 services for four Phase 2 clinical trials that utilize a proprietary bio-
 artificial device [The Extracorporeal Liver Assist Device (ELAD(TM))] in
 patients with severe hepatic disease.  Among the clinical populations to be
 evaluated are patients awaiting liver transplantation and patients who require
 medical support pending improvement in their intrinsic liver function.
     Kenneth M. Borow, M.D., Chief Executive Officer at Covalent, commented,
 "We are honored to have the opportunity to provide important research and
 development services for this exciting and innovative clinical program.
 ELAD(TM), which uniquely combines biological and device technologies,
 represents a major advancement in the struggle for survival in patients with
 severe liver disease.  In order to understand ELAD(TM)'s potential impact, the
 following should be considered.  In the United States alone, nearly
 15,000 people await life-saving liver transplants.  Due to a longstanding and
 continuing paucity of donor organs, many patients die while awaiting available
 livers.  More than 1,300 patients needing a liver transplant died in 1998, the
 last year such data were available.  The most ill patients -- those with acute
 liver failure or severe complications of chronic liver disease -- often do not
 survive the wait or become too sick to qualify for liver transplantation.
 ELAD(TM) could provide these patients with the real possibility for survival.
 From Covalent's perspective, the ELAD(TM) program is an excellent example of
 Covalent's ability to: (1) establish relationships with new clients who have
 novel state-of-the-art approaches to satisfying unmet medical needs and (2)
 provide high-quality, customized, full-service research and development
 capabilities to the drug, biologics, and device industries worldwide."
 
     The Covalent Group is a total research management and drug development
 organization. Through its consultative, operational and technologic expertise,
 The Covalent Group is setting the standard in new approaches to drug
 development and clinical trial safety.  In addition, through its SpeedTrials
 collaboration and its proprietary TeleTrial(R) interactive speech recognition
 system, Covalent is on the cutting edge of advanced clinical trial processes.
 
     This press release contains forward-looking statement identified by words
 such as "believe," "expect," and similar expressions.  Actual results might
 differ materially from those projected in, expressed in or implied by the
 forward-looking statements.  Potential risks and uncertainties that could
 affect the Company's future operation results include, without limitation:
 (I) the Company's success in attracting new business; (ii) the size, duration,
 and timing of clinical trials; and (iii) the termination, delay or
 cancellation of clinical trials.  Additional information concerning factors
 that could cause actual results to materially differ from those in
 forward-looking statements is contained in Covalent's SEC filings, including
 periodic reports under the Securities Exchange Act of 1934, as amended, copies
 of which are available upon request from Covalent's investor relations
 department.
 
     Company Contact:  Thomas Dean, Investor Relations, 212-421-2545.
 
     Contact them on-line:  http://www.covalentgroup.com.
 
 

SOURCE Covalent Group, Inc.
    WAYNE, Pa., April 4 /PRNewswire/ -- Covalent Group, Inc. (Nasdaq:   CVGR)
 announced today the signing of a $2.9 million contract with VitaGen, Inc., a
 privately held biotechnology and medical products company located in La Jolla,
 CA.  Covalent will provide advanced consultative and clinical development
 services for four Phase 2 clinical trials that utilize a proprietary bio-
 artificial device [The Extracorporeal Liver Assist Device (ELAD(TM))] in
 patients with severe hepatic disease.  Among the clinical populations to be
 evaluated are patients awaiting liver transplantation and patients who require
 medical support pending improvement in their intrinsic liver function.
     Kenneth M. Borow, M.D., Chief Executive Officer at Covalent, commented,
 "We are honored to have the opportunity to provide important research and
 development services for this exciting and innovative clinical program.
 ELAD(TM), which uniquely combines biological and device technologies,
 represents a major advancement in the struggle for survival in patients with
 severe liver disease.  In order to understand ELAD(TM)'s potential impact, the
 following should be considered.  In the United States alone, nearly
 15,000 people await life-saving liver transplants.  Due to a longstanding and
 continuing paucity of donor organs, many patients die while awaiting available
 livers.  More than 1,300 patients needing a liver transplant died in 1998, the
 last year such data were available.  The most ill patients -- those with acute
 liver failure or severe complications of chronic liver disease -- often do not
 survive the wait or become too sick to qualify for liver transplantation.
 ELAD(TM) could provide these patients with the real possibility for survival.
 From Covalent's perspective, the ELAD(TM) program is an excellent example of
 Covalent's ability to: (1) establish relationships with new clients who have
 novel state-of-the-art approaches to satisfying unmet medical needs and (2)
 provide high-quality, customized, full-service research and development
 capabilities to the drug, biologics, and device industries worldwide."
 
     The Covalent Group is a total research management and drug development
 organization. Through its consultative, operational and technologic expertise,
 The Covalent Group is setting the standard in new approaches to drug
 development and clinical trial safety.  In addition, through its SpeedTrials
 collaboration and its proprietary TeleTrial(R) interactive speech recognition
 system, Covalent is on the cutting edge of advanced clinical trial processes.
 
     This press release contains forward-looking statement identified by words
 such as "believe," "expect," and similar expressions.  Actual results might
 differ materially from those projected in, expressed in or implied by the
 forward-looking statements.  Potential risks and uncertainties that could
 affect the Company's future operation results include, without limitation:
 (I) the Company's success in attracting new business; (ii) the size, duration,
 and timing of clinical trials; and (iii) the termination, delay or
 cancellation of clinical trials.  Additional information concerning factors
 that could cause actual results to materially differ from those in
 forward-looking statements is contained in Covalent's SEC filings, including
 periodic reports under the Securities Exchange Act of 1934, as amended, copies
 of which are available upon request from Covalent's investor relations
 department.
 
     Company Contact:  Thomas Dean, Investor Relations, 212-421-2545.
 
     Contact them on-line:  http://www.covalentgroup.com.
 
 SOURCE  Covalent Group, Inc.